Sign in

PTN on Nasdaq

PALATIN TECHNOLOGIES INC

PALATIN TECHNOLOGIES INC is an American pharmaceutical preparations company based in Cranbury.2 Its shares trade on Nasdaq under the symbol PTN.2

Price unavailable

Last updated Oct 21, 2026.

Overview

$13.2MRevenue, fiscal 20263
-$8.4MNet income, fiscal 20263

Compare with Tonix Pharmaceuticals, Evommune, Inc. or CV Sciences, Inc., or pick any stock.

  • TickerPTN on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersCranbury, United States2
  • Incorporated inNJ4
  • Business address4B Cedar Brook Drive, Cranbury, Nj 085124
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI549300IDN7TWMQI0JP932
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 21085102

See how the biggest companies compare on our leaderboards

MC4R agonist intended for once-weekly subcutaneous administration and a next-generation oral small molecule MC4R agonist.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-65.7%Operating margin3
-63.5%Net margin3
-125.3%Return on equity3
-$13.6MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Research and development60¢$12.4M
  • Income tax40¢$8.4M

Out of $13.2M in revenue.3 The company lost money this year.

Financial statements

Revenue7891011123$13.2M in 2026−78% since 2019
-$20.0M0$20.0M$40.0M$60.0M$80.0M2019: $60.3M$60.3M20192020: $118.0K$118.0K2020−100%2021: -$188.6K-$188.6K20212022: $1.5M$1.5M20222023: $4.9M$4.9M2023+231%2024: $4.5M$4.5M2024−7%2025: $0$020252026: $13.2M$13.2M2026
Operating income7891011123-$8.7M in 2026
-$40.0M-$20.0M0$20.0M$40.0M2019: $35.7M$35.7M20192020: -$23.6M-$23.6M20202021: -$33.4M-$33.4M2021+41%2022: -$36.6M-$36.6M2022+10%2023: -$32.5M-$32.5M2023−11%2024: -$22.5M-$22.5M2024−31%2025: -$17.5M-$17.5M2025−22%2026: -$8.7M-$8.7M2026−50%
Net income7891011123-$8.4M in 2026
-$40.0M-$20.0M0$20.0M$40.0M2019: $35.8M$35.8M20192020: -$22.4M-$22.4M20202021: -$33.6M-$33.6M2021+50%2022: -$36.2M-$36.2M2022+8%2023: -$24.0M-$24.0M2023−34%2024: -$29.7M-$29.7M2024+24%2025: -$17.3M-$17.3M2025−42%2026: -$8.4M-$8.4M2026−52%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2026-06-302025-06-30
Collaboration and license$13.2M
Research and development$12.4M$14.9M
General and administrative$9.5M$7.8M
Gain on sale of Vyleesi-$3.1M
Gain on purchase commitment-$2.1M
Total operating expenses$21.9M$17.5M
Loss from operations-$8.7M-$17.5M
Investment income$297.1K$167.7K
Foreign currency transaction loss-$50
Interest expense-$6.7K-$15.0K
Total other income, net$290.4K$152.6K
NET LOSS-$8.4M-$17.3M
Basic net loss per common share-$2.96-$32.15
Diluted net loss per common share-$2.96-$32.15
Weighted average number of common shares outstanding used in computing basic net loss per common share2.8M shares538.3K shares
Weighted average number of common shares outstanding used in computing diluted net loss per common share2.8M shares538.3K shares

Compare PALATIN TECHNOLOGIES INC with another company

Corporate structure

PALATIN TECHNOLOGIES INC sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PALATIN TECHNOLOGIES INC

  • PALATIN TECHNOLOGIES INC Cranbury, New Jersey, United States
    • RhoMed Incorporated Subsidiary · New Mexico, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PALATIN TECHNOLOGIES INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$1.2M12 Jun 30, 2025$1.2M12 Jun 30, 20240%
Leasehold improvements$1.2M12 Jun 30, 2025$1.2M12 Jun 30, 20240%
Property and equipment, before depreciation$3.7M3 Jun 30, 2026$3.6M3 Jun 30, 2025+1.4%
Accumulated depreciation$3.6M3 Jun 30, 2026$3.5M3 Jun 30, 2025+1.8%
Property and equipment, net$118.1K3 Jun 30, 2026$129.4K3 Jun 30, 2025−8.8%
Operating-lease assets (leased space)$219.7K3 Jun 30, 2026$161.2K3 Jun 30, 2025+36.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.5M3 Jun 30, 2026$2.6M3 Jun 30, 2025+192.2%

Properties, in its own words

Our corporate offices are located at 301 Carnegie Center Drive, Suite 304, Princeton, New Jersey, where we lease office space under an agreement that expires in January 2029, subject to renewal provisions. We also lease approximately 3,600 square feet of laboratory space in Monmouth Junction, Township of South Brunswick, New Jersey, under a lease that expires in January 2030. Our corporate offices are used primarily for administrative and business activities, and our laboratory facility supports our research and development activities. We do not own any real property. We believe that our existing facilities are adequate for our current needs.

Item 2 of the 10-K filed Sep 28, 2026.6

Leadership

Who has led PALATIN TECHNOLOGIES INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Carl Spana2006–now

President

  1. Carl Spana2006–now

Chief financial officer

  1. Stephen T. Wills2006–now

Chief operating officer

  1. Stephen T. Wills2011–now
2010201520202025
Board members and other officers (14)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • RhoMed Incorporated New Mexico5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • INTERFILM INCJul 23, 1996 to Jun 14, 19964

Timeline

  1. Aug 3, 20268-K Shareholder vote31
  2. May 18, 20268-K Listing notice or transfer; Regulation FD disclosure32
  3. Dec 19, 20258-K Shareholder vote33
  4. Nov 12, 20258-K Other events34
  5. Nov 6, 20258-K Entered a material agreement; Other events35
  6. Sep 22, 20258-K Other events36
  7. Sep 10, 20258-K Other events37
  8. Aug 18, 20258-K Entered a material agreement; Regulation FD disclosure38
  9. Aug 11, 20258-K Regulation FD disclosure39
  10. Aug 8, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure40
  11. Jul 29, 20258-K Shareholder vote41
  12. Jul 9, 20258-K Listing notice or transfer42
  13. Oct 11, 2006New chief executive Carl Spana becomes CEO15
  14. Nov 21, 1986Founded PALATIN TECHNOLOGIES INC is founded2

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202643

When it reported results

  1. Nov 14, 2024Reported quarterly or annual results44
  2. Oct 1, 2024Reported quarterly or annual results45
  3. May 15, 2024Reported quarterly or annual results46
  4. Feb 15, 2024Reported quarterly or annual results47
  5. Nov 14, 2023Reported quarterly or annual results48
  6. Oct 19, 2023Reported quarterly or annual results49
  7. Sep 28, 2023Reported quarterly or annual results50
  8. May 16, 2023Reported quarterly or annual results51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

242 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 64 major events, 64 insider forms, 13 large holders, 81 other. The latest 20:

  1. Sep 28, 202610-K EDGAR
  2. Aug 14, 2026SCHEDULE 13G/A EDGAR
  3. Aug 5, 20264 EDGAR
  4. Aug 5, 20264 EDGAR
  5. Aug 5, 20264 EDGAR
  6. Aug 3, 20268-K EDGAR
  7. Jul 17, 20264 EDGAR
  8. Jul 17, 20264 EDGAR
  9. Jun 25, 2026DEF 14A EDGAR
  10. May 28, 20268-A12B EDGAR
  11. May 28, 202625 EDGAR
  12. May 28, 2026CERT EDGAR
  13. May 18, 20268-K EDGAR
  14. May 15, 2026SCHEDULE 13G/A EDGAR
  15. May 15, 2026SCHEDULE 13G/A EDGAR
  16. May 15, 2026SCHEDULE 13G EDGAR
  17. May 13, 202610-Q EDGAR
  18. Apr 23, 2026SCHEDULE 13G EDGAR
  19. Feb 17, 202610-Q EDGAR
  20. Feb 17, 2026SCHEDULE 13G EDGAR

The 242 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 7 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 24, 2025WILLS STEPHEN TExecutive VP and CFO/COOSale565$16.74$9.5KForm 4
Jun 13, 2025WILLS STEPHEN TExecutive VP and CFO/COOBuy1,500$150,000.00$225.0MForm 4
Jun 13, 2025SPANA CARLPresident and CEOBuy1,500$150,000.00$225.0MForm 4
Jun 13, 2025DUNTON ALAN WDirectorBuy200$20,000.00$4.0MForm 4
May 7, 2025DEVEER ROBERT K JRDirectorBuy100,000$0.10$10.0KForm 4
Aug 1, 2024WILLS STEPHEN TExecutive VP and CFO/COOSale4,999$1.66$8.3KForm 4
Apr 11, 2024DEVEER ROBERT K JRDirectorBuy6,000$2.12$12.7KForm 4
Mar 6, 2024DEVEER ROBERT K JRDirectorSale11,700$2.00$23.4KForm 4
Dec 6, 2023WILLS STEPHEN TExecutive VP and CFO/COOSale4,998$2.52$12.6KForm 4
Dec 4, 2023DUNTON ALAN WDirectorSale200$2.48$496Form 4
Dec 27, 2022SPANA CARLPresident and CEOBuy10,000$2.23$22.3KForm 4
Dec 27, 2022WILLS STEPHEN TExecutive VP and CFO/COOBuy10,000$2.22$22.2KForm 4
Dec 21, 2022DUNTON ALAN WDirectorSale200$2.97$594Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Carl SpanaPh.D.,$721.0K$738.5K59
2025Stephen T. WillsMST, CPA,$670.0K$688.0K59
2024Chief Executive Officer and President$700.0K$1.4M59
2024Chief Financial OfficerChief Operating Officer and Executive Vice President$650.0K$1.4M59

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Driehaus Capital Management LLC166,713$1.8M0.0%No change
Jupiter Topco LLC140,000$1.5M0.0%New
Logos Global Management LP130,000$1.4M0.1%−10,000
Ra Capital Management, L.P.62,124$670.3K0.0%−7,876
Balyasny Asset Management L.P.41,110$443.6K0.0%−59
Morgan Stanley27,272$294.3K0.0%No change
Opaleye Management Inc.20,500$221.2K0.0%New
Geode Capital Management, LLC19,382$209.2K0.0%+880
Vanguard Capital Management LLC18,911$204.1K0.0%−68
Miller Financial Services LLC15,000$161.8K0.1%+2,400
LPL Financial LLC12,552$135.4K0.0%−3
Woodline Partners LP11,244$121.3K0.0%New
Vanguard Fiduciary Trust Co8,842$95.4K0.0%+68
BlackRock, Inc.5,652$61.0K0.0%New
UBS Group AG2,986$32.2K0.0%−343
Vanguard Global Advisers, LLC1,250$13.5K0.0%No change
Tower Research Capital LLC (TRC)593$6.4K0.0%+255
Osaic Holdings, Inc.170$1.8K0.0%+1
Jones Financial Companies Lllp155$1.8K0.0%+5
Us Bancorp \de\125$1.3K0.0%No change
SBI Securities Co., Ltd.107$1.2K0.0%+94
West Paces Advisors Inc.12$1290.0%New
Barclays PLC10$1080.0%New
Wells Fargo & Company/mn4$430.0%−4
Citigroup Inc0$40.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How PALATIN TECHNOLOGIES INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPALATIN TECHNOLOGIES INC1
  • CIK0000911216
  • Employer ID (EIN)95-40788846
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company6
  • Incorporated inDelaware6
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4B Cedar Brook Drive, Cranbury, NJ 085121
  • Phone609-495-22001
  • Shares outstanding1,780,939 shares as of Sep 25, 20266
  • Public float$25.7M as of Dec 31, 20256
  • AuditorKPMG LLP, Philadelphia, Pennsylvania PCAOB ID 185; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceMay 16, 19961
  • Filings1,155 in all: 4 (382), 8-K (240), 10-Q (79), SC 13G/A (45), CORRESP (38), DEF 14A (31), 10-K (26), 424B3 (26)1
    All 59 form types

    SC 13G (23), S-3 (22), UPLOAD (22), 424B5 (16), 4/A (15), EFFECT (15), 5 (14), 10QSB (12), S-8 (12), 3 (11), DEFA14A (10), PRE 14A (10), S-1/A (8), S-3/A (8), CT ORDER (7), S-1 (7), SCHEDULE 13G (7), SC 13D (5), 10KSB (4), 10QSB/A (4), 144 (4), 424B4 (4), ARS (4), SCHEDULE 13G/A (4), 10-K/A (3), 10KSB/A (3), 8-K/A (3), NO ACT (3), PRER14A (3), 8-A12B (2), DRS (2), RW (2), 10-K405 (1), 25 (1), 3/A (1), 424B2 (1), CERT (1), D (1), DEF 14C (1), DEFS14A (1), NT 10-Q (1), POS AM (1), PRE 14C (1), PREM14A (1), PRES14A (1), REGDEX (1), RW WD (1), S-3MEF (1), SB-2 (1), SC 13D/A (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Sep 28, 2026
    Quarterly report (10-Q) May 13, 2026
    Proxy statement (DEF 14A) Jun 25, 2026
    Latest 8-K (8-K) Aug 3, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $.01 per sharePTNNasdaq

From the cover page of the 10-K filed Sep 28, 2026 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

The risks PALATIN TECHNOLOGIES INC names in Item 1A of its 10-K filed Sep 28, 2026: 46 risks under these headings, as written.6

  • Our management has determined that there is substantial doubt about our ability to continue as a going concern, which make it more difficult and more expensive for us to raise capital.
  • We have a history of substantial net losses, including a net loss of $8.4 million for the year ended June 30, 2026. We expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability.
  • We will need additional funding, including funding to complete clinical trials for our product candidates, which may not be available on acceptable terms, if at all.
  • We have limited experience successfully commercializing pharmaceutical products, and our experience with Vyleesi may not be indicative of our ability to successfully develop or commercialize our current or future product candidates.
  • Raising additional capital may cause dilution to existing stockholders, restrict our operations, or require us to relinquish rights.
  • Our business strategy is increasingly focused on the development of our MC4R agonist programs for rare obesity disorders, and these programs are at an early stage of development and may not be successful.
  • We depend on our collaborations and licensing arrangements with third parties, including Boehringer Ingelheim and Altanispac Labs, to successfully develop and commercialize certain of our product candidates, and we may not receive anticipated milestone payments, royalties or other economic benefits from these arrangements.
  • We may not receive the contingent payment retained in connection with our settlement with Cosette relating to Vyleesi.
  • Geopolitical conflicts and instability could disrupt our operations, increase economic uncertainty and volatility in financial markets, and adversely affect our business, financial condition and results of operations.
  • Our MC1R product candidates, including PL8177 for the treatment of ulcerative colitis, are still in the early stages of development and remain subject to clinical testing and regulatory approval. If we are unable to successfully develop and test our product candidates, we will not be successful.
  • If clinical trials for our product candidates are prolonged or delayed, we may be unable to commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales.
  • We may not be able to secure and maintain relationships with research institutions and other organizations to conduct our clinical trials.
The other 34 risks
  • Even if our product candidates receive regulatory approval, they may never achieve market acceptance, in which case our business, financial condition and results of operations will be materially adversely affected.
  • Even if our product candidates receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.
  • If side effects emerge that can be linked to any of our product candidates (either while they are in development or after they are approved and on the market), we may be required to perform lengthy additional clinical trials, change the labeling of any such products, or withdraw such products from the market, any of which would hinder or preclude our ability to generate revenues.
  • We may not be able to keep up with the rapid technological change in the biotechnology and pharmaceutical industries, which could make any future approved products obsolete and reduce our revenue.
  • Competing products and technologies may make our product candidates less competitive or obsolete and may adversely affect the commercial potential of our development programs.
  • We rely on third parties over whom we have no control to conduct preclinical studies, clinical trials and other research for our product candidates and their failure to timely perform their obligations could significantly harm our product development.
  • We depend on third-party manufacturers and suppliers for our product candidates, and any inability to obtain adequate supplies of materials or product candidates of acceptable quality on a timely basis could delay or adversely affect our development programs.
  • We currently have limited sales, marketing and distribution capabilities, and if we are unable to establish appropriate commercialization capabilities or enter into arrangements with third parties to commercialize our product candidates, we may be unable to successfully commercialize any products that receive regulatory approval.
  • Our ability to successfully commercialize any approved product candidates will depend in part on obtaining adequate pricing, coverage and reimbursement from governmental authorities, private health insurers and other third-party payers, which may be difficult to obtain or maintain.
  • We may be subject to product liability claims arising from the testing, manufacture or commercialization of our product candidates or products, which could result in substantial liabilities and adversely affect our business.
  • Cybersecurity incidents, failures of our information technology systems or those of third parties upon which we rely, or unauthorized access to or disclosure of confidential information could disrupt our operations, compromise sensitive information and adversely affect our business.
  • We use artificial intelligence and machine learning technologies in certain of our research and drug discovery activities, and the use of these technologies may not produce the anticipated benefits and could expose us to additional risks.
  • We may be subject to claims that our employees, consultants, collaborators or other third parties with whom we work have wrongfully used or disclosed confidential information, trade secrets or other intellectual property of third parties.
  • We are subject to healthcare laws and regulations, including fraud and abuse, false claims, transparency, and data privacy and security laws, and failure to comply with these laws could result in substantial penalties and adversely affect our business.
  • We are highly dependent on our management team, scientific and technical personnel and third-party contractors, consultants and collaborators, and the loss of their services or our inability to attract and retain qualified personnel could materially and adversely affect our business.
  • Both before and after regulatory approval, our product candidates are subject to extensive and continuing regulatory requirements, and failure to comply with these requirements could delay development, prevent or limit commercialization, or result in significant penalties.
  • The regulatory approval process is lengthy, expensive and uncertain, and may prevent us from obtaining the approvals that we require.
  • Legislative, regulatory or policy changes could increase the costs of developing or commercializing our product candidates, delay or prevent regulatory approval, or otherwise adversely affect our business.
  • Changes in healthcare laws, drug pricing, reimbursement policies and other healthcare reforms could adversely affect our business and the commercial potential of our product candidates
  • If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming.
  • If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.
  • Our patent applications and the enforcement or defense of our issued patents may be impacted by the application of or changes in U.S. and foreign standards.
  • We may not be able to protect our intellectual property rights throughout the world.
  • If we are unable to keep our trade secrets confidential, our technologies and other proprietary information may be used by others to compete against us.
  • The market price of our common stock has been, and is likely to continue to be, highly volatile, and investors may lose all or a substantial portion of their investment.
  • If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, our ability to produce accurate and timely financial statements or comply with applicable reporting requirements could be impaired, which could adversely affect our business and the market price of our common stock.
  • If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.
  • Holders of our Series A Preferred Stock and Series D Preferred Stock may have interests different from our common stockholders.
  • Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gains.
  • Anti-takeover provisions of Delaware law and our charter documents may make potential acquisitions more difficult and could result in the entrenchment of management.
  • We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • As of September 25, 2026, there were 8,763,962 shares of common stock underlying outstanding convertible preferred stock, options, restricted stock units and warrants. Stockholders may experience dilution from the conversion of preferred stock, exercise of outstanding options and warrants and vesting and delivery of restricted stock units.
  • If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock could be delisted, which could adversely affect the market price and liquidity of our common stock and our ability to raise capital.

Legal proceedings

From time to time, we may become involved in claims and legal proceedings arising in the ordinary course of our business. We are not currently a party to any legal proceedings that we believe are material to our business, financial condition or results of operations.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59